Article

Clinical efficacy and immunity of a novel immune-modulatory peptide vaccine against IDO/PD-L1 (IO102/IO103) in combination with nivolumab in patients with metastatic melanoma

2021-03-01

Abstract excerpt

<title>Abstract</title> <p>Anti-PD-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, >50% of the patients progress due to resistance. Improved combination therapies enhancing aPD1 efficacy without leading to increased toxicity are needed. In this non-randomized phase I/II study (ClinicalTrials.gov: NCT03047928), we treated 30 aPD1 naive MM patients with a novel immune-modulatory va...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 871f9219-1f8f-5a2b-9b3b-b43e2a0420aa
DOI: 10.21203/rs.3.rs-257411/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical efficacy and immunity of a novel immune-modulatory peptide vaccine against IDO/PD-L1 (IO102/IO103) in combination with nivolumab in patients with metastatic melanomaDOI 10.21203/rs.3.rs-257411/v1Read

Safety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1Semantic proximity Read

Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialSemantic proximity Read

Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanomaSemantic proximity Read

The Targeting of Indoleamine 2,3 Dioxygenase ‐Mediated Immune Escape in CancerSemantic proximity Read

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).Semantic proximity Read

Multiomics analysis reveals a Type III driven immune response in immunotherapy-induced toxicity in melanoma and identifies potential new therapeutic targetsSemantic proximity Read

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen–Specific CD8+ T Cells Induced by Melanoma VaccinesSemantic proximity Read

IMPACT - Phase Ib Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell CarcinomaSemantic proximity Read

Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumabSemantic proximity Read

Novel Immune Drug Combination Induces Tumour Microenvironment Remodelling and Reduces the Dosage of Anti-PD-1 AntibodySemantic proximity Read

HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.Semantic proximity Read

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of GlioblastomaSemantic proximity Read